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Aikuisen rasvakudoksen kantasolut (adipose stem cells, ASCs) ovat multipotentteja, 
mesenkymaalisia kantasoluja. Niillä on useita kliinistä käyttöä suosivia ominaisuuksia, kuten kyky 
erilaistua luu-, rusto- ja rasvakudoksen suuntaan, hyvä jakautumiskyky in vitro -olosuhteissa sekä 
moniin muihin kantasolulähteisiin verrattuna helppo ja vaivaton eristysmenetelmä. Nykyisiä 
soluviljelymenetelmiä tulisi kuitenkin kehittää, mikäli pyritään kantasoluterapian käyttöön 
rutiinihoitona. 
Työssä tutkittiin rasvakudoksen kantasolujen ominaisuuksia eri viljelyolosuhteissa, jotta voitaisiin 
kehittää kantasoluhoitojen turvallisuutta ja laatua. Tutkimus toteutettiin eristämällä neljän 
luovuttajan rasvakudosnäytteistä kantasolut, ja toistamalla samat toimenpiteet ja kokeet eri 
olosuhteissa: 1) ihmisen seerumia sisältävä kasvatusliuos, 2) naudan seerumia sisältävä 
kasvatusliuos sekä 3) täysin seerumiton ja eläinperäisistä aineista vapaa kasvatusliuos. Työn 
tarkoituksena oli tutkia kasvatusliuoksen makromolekulaarisen täytön (macromolecular crowding, 
MMC) eli Ficollin lisäyksen vaikutusta soluihin ja kykyä tukea soluja tuottamaan luonnollista 
mikrotason elinympäristöä laboratorio-olosuhteissa.  Työssä tutkittiin edellä mainittujen 
olosuhteiden vaikutusta solujen morfologiaan, lisääntymiseen, immunofenotyyppiin, DNA:n 
määrään ja metaboliseen aktiivisuuteen sekä erilaistuskykyyn. 
Tutkimuksessa havaittiin, että solujen pintaproteiinien ilmentyminen ei muuttunut merkittävästi, 
mutta vaikutukset erilaistumiseen, morfologiaan ja erityisesti jakautumiseen olivat huomattavia. 
Työn perusteella MMC-menetelmä seerumittomissa olosuhteissa ei sovellu rasvakudoksen 
kantasoluille, sillä pitkäkestoinen viljely ei ole mahdollista. MMC-menetelmää voidaan kuitenkin 
käyttää tukemaan erilaistumista seerumia sisältävissä kasvatusolosuhteissa. 
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1 Introduction 
Autologous, multipotent stem cells have enormous potential when it comes to clinical research and 
tissue engineering. One source of such cells is human adipose tissue. Adipose stem/stromal cells 
(ASCs) are multipotent cells of mesenchymal origin, and they have the ability to differentiate 
toward multiple mesenchymal cell types, such as adipose, bone and cartilage cells. After their 
discovery in the beginning of the century, ASCs have quickly proven to have several beneficial 
characteristics that favor their usage in cell therapy. They are abundant and accessible just beneath 
the skin in subcutaneous tissue and possess wide differentiation capacity as well as promising 
cultivation properties, such as relatively high in vitro-proliferation rate (1,2). The field of tissue 
engineering has grown tremendously over the past ten to twenty years and researchers have worked 
hard to master the properties of stem cells and to enable their utilization in every day medicine. 
However, much remains to be discovered and at the moment, despite their promising features and 
the increasing number of clinical studies using ASCs, we only have a grasp of the basics of their 
differentiation. Especially the molecular and transcriptional events of adipose stem cells remain 
poorly understood. 
When it comes to tissue engineering with medical purposes, it is clear that the current methods for 
cultivation are not adequate to provide reliable results or to ensure the safety of the final product. 
Traditionally, in vitro culture medium has been supplemented with fetal bovine serum (FBS) due to 
its availability, low price and capability to support cell growth in culture. In clinical therapy, 
however, using reagents of animal origin should be avoided to minimize complications in result of 
interspecific interplay. Thus FBS and other similar products are not ideal for clinical use (3,4). To 
avoid these issues while attempting to satisfy the needs of the cultured cells, alternative methods 
have been developed: cells have been cultured with human serum (HS) or platelet-derived 
supplements (5) as well as with xeno- and serum-free (XF/SF) supplements, developed only quite 
recently (6). Replacing all animal-derived components with these XF/SF reagents is still relatively 
marginal and thus there are no appropriate, standardized methods available for cultivation of stem 
cells with the exception of only a few cell types. 
Unfortunately, the question around serum is not the only problem concerning culture conditions. 
Choosing the components of a culture medium is based on two different needs: the cells requiring 
an environment close to their natural in vivo-habitat, and, on the other hand, the scientist trying to 
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maintain beneficial in vitro-conditions. In practice this means using only vital components to fulfill 
the needs of the cells, which extremely poorly, however, matches the concentrations in living 
tissues (7).  This is the reality especially in regard to the overall concentration of the medium. The 
protein components mimicking plasma are alone responsible for the macro-environment of the 
culture dish and so the macro-molecular concentration may only be fractions of the corresponding 
in reality. The situation is quite off-balanced since it is well known that the macro-environment 
affects the formation and remodeling of extracellular matrix (ECM) and so has an influence on 
many key elements, including formation of cytoskeleton, enzymatic reactions, adhesion and 
migration (7,8).  
As to how much the macro-environment affects the growth and development of cultured cells is not 
fully understood but especially the joint effect of different factors – different medium components 
on different cell types – is poorly known. A method altering the concentration of the medium called 
macromolecular crowding (MMC) has only been studied with bone marrow mesenchymal stem 
cells in more traditional culture media containing FBS (7), whereas the possibilities in regard to cell 
therapy appear to be promising with adipose stem cells. ASCs on the other hand have well-defined 
XF/SF culturing protocols. Managing to combine these two might just get us closer to reality – 
bringing in vivo in vitro that is.  
2 Human adipose stem cells: discovery, definition and promising 
features  
Human adult adipose stem cells were discovered as recently as in 2001. It was plastic surgeon Dr. 
Marc Hendrick and his coworkers who tried to culture tissue material collected in a liposuction but, 
by accident, ended up killing most of the cells. Only a small population survived and appeared to be 
unusually resistant. The finding quickly proved to be remarkable since it was soon understood that 
these cells could be cultured, differentiated and modified with relative ease, and more material 
could be acquired effortlessly. Since Zuk et al. (9) posted their findings, the interest in and number 
of clinical studies using ASCs has been gradually and steadily rising.  
Stem cell is defined as an ”undifferentiated cell that can continue dividing indefinitely, throwing off 
daughter cells that can either commit to differentiation or remain a stem cell in the process of self-
renewal” (10). In humans, such cells can be divided into two categories: embryonic stem cells 
derived from the inner cell mass of an early embryo and capable of giving rise to all the cell types in 
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an individual, and adult stem cells found in various tissues in a fully developed human being but 
having more limited differentiation possibilities. Adult stem cells can further be divided according 
to the germ layer they originate from: ectoderm, endoderm and mesoderm, the latter giving rise to 
mesenchyme, a primitive meshwork of embryonic connective tissue. Like all connective tissues, 
adipose tissue is derived from mesenchyme thus making ASCs stromal or mesenchymal stem cells 
(MSCs). The International Society for Cellular Therapy (ISCT) has defined minimal criteria in 
order to define MSCs of human origin: (i) they must be plastic-adherent when maintained in 
standard culture conditions; (ii) they must express certain markers (such as CD73, CD90 and 
CD105) while lacking the expression of others (such as hematopoietic markers CD14 and CD45 
and human leukocyte antigen HL-DRA); and (iii) they must be able to differentiate to osteoblasts, 
adipocytes and chondroblasts in vitro (11).   
When it comes to the clinical use of adult stem cells, there are some more or less vital criteria that 
need to be fulfilled. Firstly, it is important that the cells are found in abundance (millions to billions 
of cells) to provide enough material for cell culture, and it must be possible to harvest them with 
minimally invasive procedures. The cells should be able to differentiate along several different cell 
lineage pathways in a reproducible manner and under the control of the scientists. It should also be 
possible to transplant the cells safely and effectively either to an autologous or an allogeneic host. 
Lastly, all this should be able to be conducted according to Good Laboratory and Manufacturing 
Practice (GLP and GMP) (12).   
Much of the research conducted with mesenchymal stem cells has been based on MSCs found in 
bone marrow (BM-MSCs). Especially the differentiation possibilities and immunogenic qualities of 
these multipotent stem cells make them possible candidates for cell therapy. Unfortunately 
problems arise, including those concerning harvesting as it can be extremely painful and still tends 
to result in low cell count. However, it has been shown that ASCs possess similar morphological 
and immunophenotypical characteristics compared to other MSCs. Isolation success rate, colony 
frequency and differentiation capacity are similar to other MSCs as well (9,13,14) while they have 
the major benefit of effortless collection. Based on all these facts, it is clear that ASCs could, at 
their best, represent a source of stem cells that could enable and result in a multitude of new 
innovations. 
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3 General aspects of isolation and differentiation 
The ASC isolation techniques used today are originally based on methods developed for rat 
adipocytes and their precursors in the mid-1960s (15). By altering this protocol first for human 
adipocyte progenitors (16) and later for ASCs (2,17), we now have a standardized method that is 
applied routinely. ASCs can be found in and harvested successfully from all adipose tissues around 
the body (18) but are typically isolated either from subcutaneous samples or liposuction aspirates. 
In the former case, the sample is minced manually after detachment from the original site, whereas 
in the latter, the fat tissue is mechanically disrupted at its location within the body by entering the 
tissue through a small incision with a suction cannula. The fragmentation is further assisted by a 
collagenase treatment in a 37 °C water bath under shaking conditions. To isolate the stromal 
vascular fraction (SVF), in which also the ASCs can be found, the digested tissue is washed, 
centrifuged and filtrated in several steps with appropriate reagents to separate the SVF from the 
corresponding tissue. Furthermore, ASCs can be derived from SVF based on their plastic adherence 
property. After isolation is complete, ASCs can be cryo-preserved or plated and cultured as desired.  
ASCs can be expanded with relative ease (18) and differentiated toward multiple cell types (1,18) as 
can be demonstrated by appropriate methods (Table 1), although certain variation in protocols exist 
among different laboratories. ASCs have the ability to become osteoblasts (i) in the presence of 
ascorbate, β-glycerophosphate and dexamethasone or vitamin D3, showing extensive calcium 
deposits within their ECM. Chondrocyte differentiation (ii), marked by the secretion of cartilage 
ECM matrix proteins such as proteoglycans, collagens and aggregan, can be induced with 
transforming growth factor-β, ascorbate and L-proline. With insulin, biotin, panthotenate and 
dexamethasone ASCs can continue toward what is believed to be their natural pathway and become 
mature adipocytes (iii) gathering lipids in their vacuoles. Other, even less examined routes are the 
possibilities of becoming myocytes (iv) of skeletal muscle as well as neuronal-like cells (v), cardiac 
myocytes (vi) and smooth muscle cells (vii), vascular endothelial cells (viii), hematopoietic support 
cells (viii), and even pancreatic endocrine (ix) or hepatic cells (x) (18). However, many of these 
require extensive additional investigation and so far conclusions should be made cautiously.  
 
 
5 
 
Table 1.  Multilineage capacity of adipose stem cells and methods of differentiation and identification. (19) 
Germ	  
layer	   Cell	  lineage	   Differentiation	  stimulants	  
Histologic	  and	  
immunohistochemistry	  lineage	  
confirmation	  
Mesoderm	  
	  	  
	  	  
	  	  
	  	  
Adipogenic	   Insulin,	  3-­‐isobutyl-­‐1-­‐1-­‐methylxanthine,	  dexamethasone,	  
indomethacin,	  ciglitazone	  
AdipoRed,	  Oil	  Red	  O	  
Chondrogenic	   Insulin,	  transforming	  growth	  factor	  β1,	  ascorbate-­‐2-­‐phosphate	   Alcian	  Blue,	  collagen	  type	  II	  
Myogenic	   Hydrocortisone	   MyoD1-­‐specific	  antibodies	  
Osteogenic	   1,25-­‐Dihydroxyvitamin	  D3	  or	  dexamethasone,	  ascorbate-­‐2-­‐
phosphate,	  β-­‐glycerophosphate	  
Alkaline	  phosphatase,	  von	  Kossa	  
stain	  
Smooth	  
Muscle	  
HUVEC	  culture	  media,	  1%	  FBS,	  heparin	   Alpha	  smooth	  muscle	  actin,	  
calponin,	  and	  myosin	  heavy	  chain	  
Ectoderm	   Neurogenic	   β-­‐Mercaptoethanol	  or	  neurobasal	  medium	  supplemented	  with	  
B27	  containing	  FGF	  and	  EGF	  
Neurogenic	  proteins	  (eg,	  NeuN,	  
GFAP,	  MAP-­‐2)	  
Endoderm	  
	  	  
Endothelial	   Media	  199,	  vascular	  endothelial	  growth	  factor,	  bFGF,	  3%	  FBS	   CD31,	  CD34,	  VE-­‐cadherin	  
Hepatic	   EGF,	  activin	  A,	  bFGF,	  hepatocyte	  growth	  factor,	  nicotinamide,	  
KnockOut	  serum	  replacement	  
Periodic	  acid-­‐Schiff	  base	  stain	  
Abbreviations:	  FBS,	  fetal	  bovine	  serum;	  bFGF,	  basic	  fibroblast	  growth	  factor;	  EGF,	  epidermal	  growth	  factor;	  FGF,	  fibroblast	  growth	  
factor;	  GFAP,	  glial	  fibrillary	  acidic	  protein;	  HUVEC,	  Human	  umbilical	  vein	  endothelial	  cells;	  MAP-­‐2,	  microtubule-­‐associated	  protein-­‐
2;	  NeuN,	  neuronal	  nuclei;	  VE,	  vascular	  endothelial.	  
4 Changing the culture conditions – novel approaches 
4.1 Use of serum versus use of substitute supplements: going xeno- and serum-
free 
So far, most of the cell therapy based clinical methods require considerate amounts of cells, which 
can only be feasible through expansion in vitro when autologous material is used. In the majority of 
the research using ASCs, FBS is used as the major protein component of the culture medium 
because of its availability, low price and ability to support cell proliferation, growth and attachment. 
However, the use of animal-derived components in clinical cell therapies presents significant issues 
due to safety concerns. There have been reports of severe anaphylactic and other immune reactions 
(3,4), and the risks of viral and bacterial infections, fungi, zoonoses and prions exist (20). 
Alternatives have been developed as it would not only eliminate these issues but also remarkably 
diminish the risk of rejection. Possibly the easiest way to achieve this is by using either allogeneic 
(21) or, still better, autologous products such as human serum (22), umbilical cord serum (23), or 
alternatively components such as albumin (24), platelet-rich plasma (25,26) and platelet lysate (27). 
Then again, these are all human blood-derived products and so are associated with certain 
limitations: they may not be available for long-term cultures and their composition may vary 
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considerably between different lots or may not even be definable. To ensure the consistency, 
efficacy and safety of the procedure, all the steps in the manufacturing process of the final, 
transplanted ASCs need to be standardized. This leads us to yet another alternative: if we could 
replace all animal-derived, ill-defined components with purely synthetic XF/SF reagents, we could 
forget all the aforementioned concerns.  
There are only a mere handful of XF/SF supplements on the market today and fully defined 
cultivation protocols for them are scarce. Moreover, in the XF/SF studies reported, the isolation and 
even early expansion have often been conducted in serum-containing medium making the effort of 
avoiding exposure worthless. Taking this into consideration, Patrikoski et al. (28) were able to 
demonstrate that such procedure is in fact feasible and does not appear to affect the end result 
significantly.  
As has been demonstrated (17,28,29), ASCs retain their differentiation ability and phenotypical 
characteristics under XF/SF conditions with minor differences. Compared to serum-containing 
medium, they do have considerably shorter doubling times, which would make it possible to speed 
up the process of propagation. The flow cytometric immunophenotype analysis of ASCs prior to 
differentiation shows no other significant dissimilarities except the expression of CD54, an 
intercellular adhesion molecule, and of CD45, leukocyte common antigen. The former can be seen 
in practice especially when plating the cells: in the absence of serum, the flasks need to be pre-
coated. Even then, the very first plating is often critical since not all cells are able to adhere. Cell 
morphology proves the observation since XF/SF cells appear more spindle-shaped and smaller in 
size that do the more rounded, almost cuboidal cells grown in medium-containing serum. However, 
the low expression of CD54 may implicate that the cell population is more homogenous because of 
the more defined, more selective isolation and expansion protocols. On the other hand, CD45 is a 
protein tyrosine phosphatase receptor and is expressed on all leukocytes. It regulates the signaling 
between T- and B-cell receptors and corresponding antigens, and higher concentrations may induce 
higher immunogenic responses, as discussed below. The XF/SF cultured ASCs may show slightly 
reduced capability to gather lipids or calcium deposits in staining but, on the other hand, the 
expression of corresponding cell type-specific genes is higher compared to serum-containing 
medium (28). Per se, there are signs of differentiation and this may only be due to the nutritional 
inadequacy of the XF/SF medium. Chondrogenic differentiation, however, appears to be intensified 
and the size of the grown pellet larger. Although possibly growing with less nutrients, all these 
differences compared to serum-based cultivation may also be explained by the high proliferation 
rate. Due to technical reasons, there is plenty of space for the cells to form a large cartilage pellet 
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but especially the wells under osteogenic induction become rapidly confluent and the already 
loosely attached cells begin to detach. This happens so quickly that the differentiation only just has 
time to begin. Regardless, the minimum criteria for defining multipotent mesenchymal stem cells 
(11) is fulfilled verifying their origin, and so, by improving the current XF/SF culture methods, we 
might just get the full benefit of its advantages.  
4.2 Macromolecular Crowding –method  
The term macromolecular crowding refers to the fact that the total concentration of macromolecules 
inside a cell is so high that the actual volume available for the molecules is significantly less than 
the anatomical volume of the cell. This is the result of a phenomenon called excluded volume 
effect: the volume surrounding a certain molecule becomes unavailable for the other molecules and 
is determined by the molecular mass and shape of the first particle. When the excluded volume is 
taken into consideration, the effective concentrations of different macromolecules in the solution 
become larger and thus make their chemical activity increased as well. This in turn affects directly 
the rates and thermodynamic states of equilibrium of all their reactions. The larger the molecule, the 
greater the effect will be. In general, the major reactions involved include the binding of 
macromolecules to surfaces, the formation of macromolecular complexes and aggregates, and the 
folding of proteins; all in attempt to reduce the total excluded volume and hence the free energy of 
the system.  (30)  
Traditionally, the composition of the culture medium has been based on a principle of minimum 
requirement: using only the reagents vital for the growth and proliferation of the cells while at the 
same time trying to maintain the process as simple as possible for the cultivator. This however, 
matches extremely poorly the environment in the natural habitat of the cells. For several years now, 
there has been a growing interest and a corresponding number of studies exploring different 
scaffolds and biomaterials to mimic the natural multidimensional surface cells face in living tissues. 
The flasks and wells used in basic cell culture are flat and smooth, and the effect of surfaces should 
not be underestimated as mechanical factors are strongly correlated with the success of the culture. 
Nonetheless, we should inspect the effects of the fluid components at the same time and as eagerly 
in order to bring the medium up to date as well.  
So the minimum requirement of the medium has led us to a situation where the composition is far 
off the actual, living tissue equivalent. This is especially true with the overall macromolecular 
concentrations as the serum or plasma derivatives or other protein supplements described above are 
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alone responsible for the extracellular 
macro-environment. The high dilution of 
these components typically results in 
concentrations around 1-10 grams per liter 
compared to the much higher values in 
interstitial fluid (30-70 g/L), blood plasma 
(80 g/L) or cell cytoplasm (200-350 g/L) (7). 
The situation is very inconsistent with 
current data since it has been described on 
several occasions how the macro-
environment affects the formation of ECM 
through excluded volume and crowding 
effects, and ECM in turn directly guides the 
actions of the cells.  (7,8,30-32) (Figure 1) 
Crowding can be accomplished by several 
methods. Since serum admixture is the 
primary responsible effector, it would seem 
logical to increase its concentration. This, 
however, has been seen to result in 
excessive proliferation and other 
disturbances because of the simultaneous rise in growth factor, hormone and other metabolism-
related protein concentrations (7). Neither should it be forgotten that, for clinical purposes, the aim 
is to replace all animal-derived components, and therefore turn to synthetic materials. It is clear that 
this way authentic biological conditions cannot be reached, and so the intention is to simply mimic 
them as well as possible. One such possibly profitable material, and already widely used one, is 
polyethylene glycol. Unfortunately it has proven to be somewhat problematic since defining the 
nature of its interactions with proteins has not been possible (30). A polysaccharide called dextran is 
used as a crowder as well but its problems lie in its electronegative charge. Ficoll (trademark of GE 
Healthcare companies) then again, is an uncharged, small (diameter of 4-8 nm) and non-cytotoxic 
polymer of sucrose. It dissolves readily in aqueous solutions without altering their viscosity notably 
and, because of its neutrality, does not interact or alter the ordinary charge-dependent cellular 
reactions apart from its crowder function.  
Figure 1. The effect of macromolecular crowding on the 
reciprocity between the cell and ECM. The crowders promote ECM 
alignment which in turn affects the organization of the cytoskeleton 
and protein secretion of the cell. As a result, the overall degree of 
organization, cell adhesion and cell proliferation all increase. Modified 
from Zeiger et al (7). 
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Zeiger et al. (7) reported the effects of MMC on mesenchymal stem cells by using a mixture of 70 
and 400 kDa Ficoll as a crowding agent. With the admixture, the final concentration of the culture 
medium was set to a level corresponding to that of the protein concentration of blood plasma 
(approximately 80 mg/mL). They compared intra- and extracellular protein organization between 
cultures under MMC and without it, and were able to show that crowding itself was able to further 
the alignment of ECM even in the absence of cellular interaction. The ECM in turn affected cell-
matrix interactions and promoted adhesion, thus having an influence on the formation and structure 
of the cytoskeleton. At the same time, these crowded, more organized cells would begin to secrete 
more matrix proteins to again enhance its formation in a feedback-like manner. By promoting cell-
matrix interaction and adhesion, the crowding also increased MSC proliferation since proliferation 
has been shown to depend on initial seeding density (33), and at the same time, decreased their 
ability to migrate (Figure 1).  
However informative, the study of Zeiger et al. (7) was conducted using animal-derived serum and 
bone marrow stem cells. Furthermore, it was intentionally purely focused on ECM-cell-interactional 
mechanisms of undifferentiated cells and did not take a stand on the influence on differentiation. 
Yet, these are indeed aspects to be considered in cellular therapy. Thus by learning the peculiarities 
and means of efficient utilization of macromolecular crowding, we could, again, receive more 
consistent results.  
5 Prospects of research 
As mentioned, much remains to be examined in regard to clinical potential of ASCs. There are still 
gaps in our understanding of their essential characteristics, let alone the management of all different 
aspects together in cell culture. The escalating number of both clinical and pre-clinical studies is 
extremely encouraging and significant steps have already been taken forward in only a few years. 
5.1 An interesting feature under exploration: immunomodulatory properties 
As the fundamental goal of ASC-based research is the possibility to treat patients and human 
diseases, the same components and aspects of treatment should be considered as with any medical 
remedy. With actual medications, pharmacology is of significance, and it is essential to know how 
the drug affects the patient and, on the other hand, how the patient affects the drug. By attempting 
to avoid allogeneic reagents and thus rejection, the question of patient influencing the treatment is 
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considered, but how about the question of how the treatment – the implanted cells – affects the 
patient? 
One of ASCs’ interesting features is their capability to modulate immunogenic responses. Again, 
this function has been thoroughly proved for mesenchymal stem cells, especially for BMSCs, and 
ASCs have been much less studied. However, these two do appear to feature mainly the same basic 
principles as they are weakly immunogenic and able to suppress allogeneic lymphocyte reaction 
and proliferation (34). Puissant et al. (34) summarized the immunological properties of ASCs as 
follows: (i) they are unable to provoke allogeneic lymphocyte immune response, (ii) they inhibit 
lymphocyte proliferation, (iii) their inhibitory effect is dependent on the number of ASCs and the 
duration of contact, both being directly proportional to the inhibition, and (iv) all this requires cell-
cell contact to begin but the effect persists even after separation although slightly diminished. The 
latter observation indicates the fact that the inhibition is not only mediated by cell-cell adhesion but 
also by secretion of anti-inflammatory substances such as cytokines and chemokines, which may 
not be spontaneously produced by the ASCs but a result of allogeneic exposure (34,35). Besides 
these qualities, ASCs lack the expression of major histocompatibility complex class II (MHC-II) 
molecules and co-stimulatory molecules CD40, CD80 and CD86, the three of them being involved 
with T- and B-cell stimulation and activity (35), which again makes ASCs regulators of T-cell 
functions.  
In search of more safe and efficient cultivation protocols, it would be beneficial to replace all 
animal-derived components with more defined ones as described. The immunological properties of 
XF/SF cultured ASCs were recently explored by Patrikoski et al. (35), who discovered that the 
culture condition does influence their properties in this aspect as well. Cells cultured with FBS were 
the strongest to suppress immune reactivity but cells cultured with HS or XF/SF supplements did so 
as well and the differences were minor. However, the result is in line with significantly lower 
expression of CD54 in XF/SF cells, since this adhesion molecule plays an important role in 
mesenchymal stem cell-mediated immune suppression. Because of their immunological 
characteristics, ASCs cultured either in serum-containing medium or XF/SF medium could be 
worthy candidates for cell therapy. Even if the grafted cells were exposed to animal-derived 
components during manufacturing, or XF/SF cultured but allogeneic cells were used, 
immunological disorders and allogeneic conflicts could probably be avoided based on these results. 
Another possible application could be cell-based immunotherapy: the use of ASCs as a tool to go 
against inflammatory reactions or even as modulators of existing conventions of the autoimmune 
system. Like with all applications using ASCs though, it should first be made sure that these cells 
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are sufficiently controlled. In the case of modulating the immune system, it must be certain that the 
mechanisms vital and necessary for the patient are not suppressed as well: this might lead to events 
such as tumor formation or facilitated growth and metastasis even in the absence of uncontrolled 
differentiation (36,37).  
5.2 Clinical achievements and current trials  
Being a relatively new discovery, clinical studies aiming to treat patients with ASCs have only 
begun to be reality. Not that many trials have actually been carried through but the number keeps 
expanding. The future seems very optimistic since the possibilities of ASCs lie in so many areas of 
specialty that the number of those interested is tremendous. All the aforementioned characteristics 
of ASCs combined with the possibility to avoid all the ethical issues faced with embryonic stem 
cells for example, provide a highly prospective solution to a number of diseases. What is more, it 
would now seem that the targets of treatment are not limited to tissues of mesodermal origin but 
include those of ectodermal and endodermal origin as well. An example of all the clinical 
implications – the currently known ones and those at least hypothesized to exist, that is – was 
presented by Schaffler et al. (Table 2). Different chemical methods, such as macromolecular 
crowding, as well as mechanical tools, such as vibrations (38) and scaffolds of various materials 
(39), can be used to modulate and direct the cultivation.  
Trials based on differentiation toward 
mesenchymal lineages were the first clinical 
trials to be conducted on ASCs. There have 
been reports of bone reconstructions (40,41), 
soft tissue augmentations (42,43) and cartilage 
applications (44,45), and the potential of ASCs 
to treat skeletal muscle injuries has also been 
investigated (46). Some ongoing trials study 
the possibilities of treating defects such as 
those of cardiac muscle, vascular tissues, 
gonads and the urinary tract as well.  
Studies describing the use of ASCs in 
ectodermal conditions are much fewer. These 
include skin grafts, which have been studied 
Table 2. An example of some of the possible clinical 
applications for adipose stem cells. GVHD = graft-versus-host 
disease. (18) 
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successfully (47), but there are several trials looking even into the possibilities of repairing neuronal 
tissue. Currently the means of treatment in neurology are often insufficient and neural tissues 
themselves are considered to have an extremely poor capability to regenerate, so the newest studies 
have raised the hopes for many. Endodermal trials, then again, are aiming to find solutions to 
problems such as those of pulmonary stroma, hepatic and pancreatic tissues, and gastrointestinal 
tract. (48) 
The classical treatment pathway begins form cell implantation and then proceeds to differentiation 
and finally defect repair. A current trend in cell therapy, however, is the transition from this 
classical method to the manipulation of existing tissues by means of cellular communication. 
Through the release of different mediators and transmitter substances the grafted cells could act as 
conductors and only direct cell behavior in the implantation site. This is where the 
immunomodulatory effect especially has proven to be very promising. Of all the ongoing clinical 
trials, Crohn’s disease and articular diseases are the most studied ones and there have even been 
some clinical trials attempting to treat HIV and graft-versus-host disease for example (48). It seems 
that through immunomodulation inflammation can be diminished and immune system in general 
altered. As said previously, studies conducted with mesodermal cells are still today most common, 
but the aspect of cellular communication has notably increased the share of studies conducted with 
cells of other origins as well.  
5.3 Expectations for the future 
Therapeutically the possibilities of ASCs lie within several branches of medicine, and as novel 
aspects of ASCs are still continuously discovered, completely new applications are come up with 
regularly as well. We cannot yet know which are practicable and valuable in reality as we are still in 
the middle of the process of understanding the characteristics and requirements of ASCs. If we 
could understand the basics, we might more efficiently be able to focus on enhancing the procedure 
with mechanical and chemical techniques. Then again, these two work vice versa, and neither 
should come to a halt as they reinforce each other. As is natural and fortunate too, further research 
leads to further knowledge and always awakens new questions. As an end result, we can only 
conclude that both in vitro and in vivo clinical trials are still required before we are ready to offer 
ASCs as off-the-shelf treatments in everyday practice. Nevertheless, with all the ongoing research, 
rapid development should be expected. 
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6 Conclusions 
Until recently, all medical conditions requiring tissue repair or modulation have been treated by 
either helping the existing tissues to regenerate or by taking grafts from the patient’s own 
corresponding tissues elsewhere in the body. These methods are not always adequate or trouble-
free: bone transplants for example are painful, strenuous for the patient and still often insufficient 
and thus unsuccessful. With ASCs and cell-based therapies, however, it now seems possible to 
bypass many of these problems all the while being safely and effectively able to repair the damage. 
Moreover, with ASCs it is possible to create new material instead of having to weigh the 
advantages of tissue transfer against the many disadvantages. Compared to embryonic stem cells, 
ASCs do have some limitation such as restriction in differentiation capability, but they also have 
plenty in their favor. Though limited, their possible courses of differentiation are fairly extensive as 
they are able to head toward cells and tissues of not only mesodermal origin but ectodermal and 
endodermal as well. A relatively new yet promising approach is the manipulation of existing tissues 
through cellular communication, which could provide the solution to many immune disorders and 
immunologic diseases. Compared to many other cell types previously used in stem cell therapy, 
ASCs are easy to harvest, isolate and culture in an environment that, for the researcher too, is 
manageable and modifiable. Finally, their chemical and cyto-architectural characteristics appear 
profitable. Much remains to be investigated; yet much has already been achieved with the 
knowledge we have. Off-the-shelf regenerative medical products are not reality today but as we are 
beginning to understand and slowly master the possibilities of cell therapy in all its forms, we may 
be in the process of actualizing designs many thought were impossible.  
  
14 
 
References 
 (1) Gimble J, Guilak F. Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. 
Cytotherapy 2003;5(5):362-369. 
(2) Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: 
implications for cell-based therapies. Tissue Eng 2001 Apr;7(2):211-228. 
(3) Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A. Presence of IgE antibodies to bovine serum 
albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer 
Immunol Immunother 2000 Jun;49(3):152-156. 
(4) Selvaggi TA, Walker RE, Fleisher TA. Development of antibodies to fetal calf serum with arthus-like reactions in 
human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood 1997 Feb 1;89(3):776-
779. 
(5) Schallmoser K, Strunk D. Preparation of pooled human platelet lysate (pHPL) as an efficient supplement for animal 
serum-free human stem cell cultures. Journal of Visualized Experiments 2009(32). 
(6) Parker A, Shang H, Khurgel M, Katz A. Low serum and serum-free culture of multipotential human adipose stem 
cells. Cytotherapy 2007;9(7):637-646. 
(7) Zeiger AS, Loe FC, Li R, Raghunath M, Van Vliet KJ. Macromolecular crowding directs extracellular matrix 
organization and mesenchymal stem cell behavior. PLoS One 2012;7(5):e37904. 
(8) Ellis RJ. Macromolecular crowding: an important but neglected aspect of the intracellular environment. Curr Opin 
Struct Biol 2001 Feb;11(1):114-119. 
(9) Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of 
multipotent stem cells. Mol Biol Cell 2002 Dec;13(12):4279-4295. 
(10) Alberts B. Molecular biology of the cell. 4. ed. ed. New York: Garland Science; 2002. 
(11) Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining 
multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 
2006;8(4):315-317. 
(12) Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. Circ Res 2007 May 
11;100(9):1249-1260. 
(13) Izadpanah R, Trygg C, Patel B, Kriedt C, Dufour J, Gimble JM, et al. Biologic properties of mesenchymal stem 
cells derived from bone marrow and adipose tissue. J Cell Biochem 2006 Dec 1;99(5):1285-1297. 
(14) Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, et al. Comparative analysis of human mesenchymal stem 
cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int j mol sci 
2013;14(9):17986-18001. 
(15) Rodbell M. METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE 
METABOLISM AND LIPOLYSIS. J Biol Chem 1964 Feb;239:375-380. 
(16) Van RL, Bayliss CE, Roncari DA. Cytological and enzymological characterization of adult human adipocyte 
precursors in culture. J Clin Invest 1976 Sep;58(3):699-704. 
(17) Lindroos B, Boucher S, Chase L, Kuokkanen H, Huhtala H, Haataja R, et al. Serum-free, xeno-free culture media 
maintain the proliferation rate and multipotentiality of adipose stem cells in vitro. Cytotherapy 2009;11(7):958-972. 
15 
 
(18) Schaffler A, Buchler C. Concise review: adipose tissue-derived stromal cells--basic and clinical implications for 
novel cell-based therapies. Stem Cells 2007 Apr;25(4):818-827. 
(19) Kokai LE, Marra K, Rubin JP. Adipose stem cells: biology and clinical applications for tissue repair and 
regeneration. Transl Res 2014 Apr;163(4):399-408. 
(20) Pessina A, Bonomi A, Baglio C, Cavicchini L, Sisto F, Neri MG, et al. Microbiological risk assessment in stem 
cell manipulation. Crit Rev Microbiol 2008;34(1):1-12. 
(21) Tateishi K, Ando W, Higuchi C, Hart DA, Hashimoto J, Nakata K, et al. Comparison of human serum with fetal 
bovine serum for expansion and differentiation of human synovial MSC: potential feasibility for clinical applications. 
Cell Transplant 2008;17(5):549-557. 
(22) Perez-Ilzarbe M, Diez-Campelo M, Aranda P, Tabera S, Lopez T, del Canizo C, et al. Comparison of ex vivo 
expansion culture conditions of mesenchymal stem cells for human cell therapy. Transfusion 2009 Sep;49(9):1901-
1910. 
(23) Tekkatte C, Vidyasekar P, Kapadia NK, Verma RS. Enhancement of adipogenic and osteogenic differentiation of 
human bone-marrow-derived mesenchymal stem cells by supplementation with umbilical cord blood serum. Cell Tissue 
Res 2012 Feb;347(2):383-395. 
(24) Trivedi HL, Vanikar AV, Thakker U, Firoze A, Dave SD, Patel CN, et al. Human adipose tissue-derived 
mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. Transplant Proc 
2008 May;40(4):1135-1139. 
(25) Anitua E, Prado R, Orive G. Safety and efficient ex vivo expansion of stem cells using platelet-rich plasma 
technology. Ther deliv 2013 Sep;4(9):1163-1177. 
(26) Amable PR, Teixeira MV, Carias RB, Granjeiro JM, Borojevic R. Mesenchymal stromal cell proliferation, gene 
expression and protein production in human platelet-rich plasma-supplemented media. PLoS ONE 2014;9(8):e104662. 
(27) Bieback K. Platelet lysate as replacement for fetal bovine serum in mesenchymal stromal cell cultures. Transfus 
med hemother 2013 Oct;40(5):326-335. 
(28) Patrikoski M, Juntunen M, Boucher S, Campbell A, Vemuri MC, Mannerstrom B, et al. Development of fully 
defined xeno-free culture system for the preparation and propagation of cell therapy-compliant human adipose stem 
cells. Stem Cell Res Ther 2013 Mar 7;4(2):27. 
(29) Chase LG, Lakshmipathy U, Solchaga LA, Rao MS, Vemuri MC. A novel serum-free medium for the expansion of 
human mesenchymal stem cells. Stem Cell Res Ther 2010;1(1):8. 
(30) Zhou HX, Rivas G, Minton AP. Macromolecular crowding and confinement: biochemical, biophysical, and 
potential physiological consequences. Annu Rev Biophys 2008;37:375-397. 
(31) Ang XM, Lee MH, Blocki A, Chen C, Ong LL, Asada HH, et al. Macromolecular crowding amplifies adipogenesis 
of human bone marrow-derived mesenchymal stem cells by enhancing the pro-adipogenic microenvironment. Tissue 
Eng Part A 2014 Mar;20(5-6):966-981. 
(32) Chen C, Loe F, Blocki A, Peng Y, Raghunath M. Applying macromolecular crowding to enhance extracellular 
matrix deposition and its remodeling in vitro for tissue engineering and cell-based therapies. Adv Drug Deliv Rev 2011 
Apr 30;63(4-5):277-290. 
(33) Lode A, Bernhardt A, Gelinsky M. Cultivation of human bone marrow stromal cells on three-dimensional scaffolds 
of mineralized collagen: influence of seeding density on colonization, proliferation and osteogenic differentiation. J 
Tissue Eng Regen Med 2008 Oct;2(7):400-407. 
16 
 
(34) Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, et al. Immunomodulatory effect of human adipose 
tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol 2005 
Apr;129(1):118-129. 
(35) Patrikoski M, Sivula J, Huhtala H, Helminen M, Salo F, Mannerstrom B, et al. Different culture conditions 
modulate the immunological properties of adipose stem cells. Stem cells transl med 2014 Oct;3(10):1220-1230. 
(36) Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Immunosuppressive effect of mesenchymal stem 
cells favors tumor growth in allogeneic animals. Blood 2003 Nov 15;102(10):3837-3844. 
(37) Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour 
stroma promote breast cancer metastasis. Nature 2007 Oct 4;449(7162):557-563. 
(38) Tirkkonen L, Halonen H, Hyttinen J, Kuokkanen H, Sievanen H, Koivisto AM, et al. The effects of vibration 
loading on adipose stem cell number, viability and differentiation towards bone-forming cells. J R Soc Interface 2011 
Dec 7;8(65):1736-1747. 
(39) Zanetti AS, Sabliov C, Gimble JM, Hayes DJ. Human adipose-derived stem cells and three-dimensional scaffold 
constructs: a review of the biomaterials and models currently used for bone regeneration. J Biomed Mater Res B Appl 
Biomater 2013 Jan;101(1):187-199. 
(40) Sandor GK, Tuovinen VJ, Wolff J, Patrikoski M, Jokinen J, Nieminen E, et al. Adipose stem cell tissue-engineered 
construct used to treat large anterior mandibular defect: a case report and review of the clinical application of good 
manufacturing practice-level adipose stem cells for bone regeneration. J Oral Maxillofac Surg 2013 May;71(5):938-
950. 
(41) Pak J. Autologous adipose tissue-derived stem cells induce persistent bone-like tissue in osteonecrotic femoral 
heads. Pain physician 2012 Jan-Feb;15(1):75-85. 
(42) Jeong SH, Han SK, Kim WK. Soft tissue augmentation using in vitro differentiated adipocytes: a clinical pilot 
study. Dermatol Surg 2011 Jun;37(6):760-767. 
(43) Kim M, Kim I, Lee SK, Bang SI, Lim SY. Clinical trial of autologous differentiated adipocytes from stem cells 
derived from human adipose tissue. Dermatol Surg 2011 Jun;37(6):750-759. 
(44) Dragoo JL, Samimi B, Zhu M, Hame SL, Thomas BJ, Lieberman JR, et al. Tissue-engineered cartilage and bone 
using stem cells from human infrapatellar fat pads. J Bone Joint Surg Br 2003 Jul;85(5):740-747. 
(45) Jo CH, Lee YG, Shin WH, Kim H, Chai JW, Jeong EC, et al. Intra-articular injection of mesenchymal stem cells 
for the treatment of osteoarthritis of the knee: a proof-of-concept clinical trial. Stem Cells 2014 May;32(5):1254-1266. 
(46) Mizuno H, Zuk PA, Zhu M, Lorenz HP, Benhaim P, Hedrick MH. Myogenic differentiation by human processed 
lipoaspirate cells. Plast Reconstr Surg 2002 discussion 210-1; Jan;109(1):199-209. 
(47) Chavez-Munoz C, Nguyen KT, Xu W, Hong SJ, Mustoe TA, Galiano RD. Transdifferentiation of adipose-derived 
stem cells into keratinocyte-like cells: engineering a stratified epidermis. PLoS ONE 2013;8(12):e80587. 
(48) U.S. National Institutes of Health. ClinicalTrials.gov. 2015; Available at: 
https://www.clinicaltrials.gov/ct2/results?term=adipose+stem+cell&Search=Search. Accessed 09/10, 2015. 
  
 
